FDA Clears SPAXUS Stent, Advancing Minimally Invasive GI Treatment

LOS ANGELES, CA – May 01, 2026 – In a significant development for gastroenterological care, TaeWoong Medical USA has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Niti-S SPAXUS™ Stent. This approval allows for the commercialization of a new, minimally invasive device designed to treat complex pancreatic and gallbladder conditions, marking a key milestone for the company and offering a new therapeutic tool for physicians across the United States.

The SPAXUS™ Stent is a fully covered, self-expanding metallic stent engineered for use in endoscopic ultrasound (EUS)-guided transluminal drainage procedures. The clearance positions TaeWoong to compete in a rapidly growing market and provides a new option for patients who might otherwise face higher-risk surgical interventions.

A New Frontier in Minimally Invasive Drainage

The approval of the SPAXUS™ Stent heralds a new era for patients suffering from symptomatic pancreatic pseudocysts, walled-off necrosis, and acute cholecystitis. For decades, the treatment for these conditions often involved invasive surgery or percutaneous drainage, which carry significant risks, longer recovery times, and potential for complications. Endoscopic alternatives have been gaining favor, and devices like SPAXUS™ represent the cutting edge of this therapeutic shift.

The device’s design incorporates several features aimed at improving safety and efficacy. Its bi-flange, or dumbbell, shape is engineered to securely anchor the stent between two lumens—for example, the stomach and a pancreatic cyst—a concept known as lumen apposition. This design is critical for minimizing the risk of stent migration, a common challenge with earlier-generation devices. Furthermore, a full silicone coating covers the stent, which helps prevent leakage of fluid into the abdominal cavity and is intended to make the stent easier to remove once drainage is complete.

SPAXUS™ is specifically indicated for draining large symptomatic pancreatic pseudocysts and walled-off necrosis (collections ≥ 6 cm in size), as well as for gallbladder drainage in patients with acute cholecystitis who are deemed high-risk for surgery. The clinical data supporting the device is robust. A pivotal clinical evaluation for the treatment of pancreatic pseudocysts showed an impressive 97.1% clinical success rate, with no device-related serious adverse events reported. This level of performance underscores the stent's potential to become a reliable workhorse for interventional gastroenterologists.

Navigating a Competitive and Growing Market

TaeWoong Medical USA’s entry into the U.S. EUS drainage market with SPAXUS™ comes at a time of significant market expansion. The global endoscopic ultrasound market was valued at approximately $1.53 billion in 2024 and is projected to climb to $2.27 billion by 2030, driven by a rising prevalence of gastrointestinal disorders and a strong preference for minimally invasive procedures among both clinicians and patients. North America represents the largest segment of this market, making FDA clearance a critical step for any company with global ambitions.

The market for EUS-guided drainage devices, a subset of the broader GI device space, is particularly dynamic. These advanced tools, known as lumen-apposing metal stents (LAMS), have become the standard of care for draining pancreatic fluid collections. TaeWoong will be competing with established players like Boston Scientific, whose AXIOS™ Stent is a well-known product in this category, and other major medical device companies such as Cook Medical and Olympus that have extensive GI portfolios.

However, the growing market size suggests there is ample room for new, effective solutions. The gastrointestinal stent market alone is projected to expand from approximately $617 million in 2026 to over $792 million by 2031. TaeWoong's strategy appears to be focused on carving out a share by emphasizing clinical efficacy, device reliability, and strong support for the physicians who will use it.

Addressing Critical Needs for High-Risk Patients

The true impact of technologies like the SPAXUS™ Stent is best understood through the lens of the patients they are designed to help. Pancreatic pseudocysts and walled-off necrosis are serious complications of pancreatitis, an inflammatory condition of the pancreas. These fluid or debris-filled collections can cause severe pain, infection, and blockage, requiring urgent intervention. For patients with acute cholecystitis (gallbladder inflammation) who are too frail or ill to undergo surgery, an effective drainage solution can be life-saving.

EUS-guided drainage offers a transformative alternative. Using an endoscope equipped with an ultrasound probe, a physician can visualize the target collection through the wall of the stomach or duodenum, then precisely deploy the SPAXUS™ Stent to create a temporary drainage channel. This procedure avoids external incisions, reduces the risk of infection associated with percutaneous drains, and dramatically shortens hospital stays.

For patients with walled-off necrosis, which contains solid debris, the larger diameter of LAMS like SPAXUS™ is particularly beneficial. It not only facilitates drainage but also allows the endoscopist to pass the endoscope through the stent into the necrotic cavity to perform direct endoscopic necrosectomy—a procedure to actively remove dead tissue. This “step-up” approach from drainage to debridement has revolutionized the management of one of the most challenging GI conditions.

TaeWoong's Strategic Expansion in the U.S.

The 510(k) clearance is more than just a regulatory hurdle; it is a strategic cornerstone for TaeWoong Medical USA. As the exclusive U.S. partner of its South Korean parent company, TaeWoong Medical Co., Ltd., the California-based distributor is on a mission to expand its footprint in the lucrative American healthcare market. The clearance via the 510(k) pathway, which designates SPAXUS™ as “substantially equivalent” to existing devices, allows for a more streamlined path to market while validating its foundation in established, effective technology.

“This FDA clearance represents an important milestone for TaeWoong Medical USA as we continue to expand our advanced endoscopic solutions in the U.S. market,” said Minsoo Seo, CEO at TaeWoong Medical USA, in the company’s official announcement. “SPAXUS™ provides physicians with a reliable option for EUS-guided drainage procedures and reinforces our commitment to innovation in minimally invasive GI care.”

This move builds upon the company’s existing portfolio of esophageal, biliary, and colonic stents and radiofrequency ablation systems. By adding a sophisticated EUS therapeutic device, TaeWoong is signaling its intent to be a comprehensive provider in the advanced endoscopy space. The company's focus on clinical excellence and building relationships with healthcare professionals will be crucial as it introduces SPAXUS™ to hospitals and ambulatory surgical centers nationwide, aiming to improve procedural efficiency and, ultimately, patient outcomes.